[A20-80] Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2020
Project no.:
A20-80
Commission:
Commission awarded on 28.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Indication:
| Adults with active psoriatic arthritis who responded inadequately to DMARD therapy |
Result of dossier assessment:
| For under 65 year olds with concomitant moderate to severe plaque psoriasis who responded inadequately to DMARD therapy (except bDMARDs), under secukinumab alone: hint of considerable added benefit; other constellations: added benefit not proven |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2021-02-18: A G-BA decision was published.